This review assesses the safety and efficacy of growth hormone secretagogues (GHSs), including ghrelin mimetics and GHRH analogs, as alternatives to recombinant GH therapy. GHSs like ibutamoren, anamorelin, and macimorelin stimulate endogenous GH release, offering potential benefits in conditions such as GH deficiency, sarcopenia, and cachexia. Clinical studies indicate improvements
This review explores the controversial role of growth hormone (GH) in aging. While GH levels naturally decline with age and GH therapy has been proposed for anti-aging, evidence suggests reduced GH/IGF-1 activity is associated with increased lifespan and decreased cancer risk in animal models. Human studies on GH therapy in
This case report describes a young male patient who suffered severe traumatic brain injury (TBI) following a plane crash, resulting in spastic tetraplegia, dysarthria, dysphagia, cognitive deficits, and joint deformities. Fifteen months post-injury, the patient commenced a regimen of growth hormone (GH) therapy at 1 mg/day administered in three-month intervals
